MedTrace Logo

Senior-COVID-Rea Multicentric Survey

NCT04422340 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2020-07-30

No results posted yet for this study

Summary

With the spread of COVID-19 epidemic since 2019 in Wuhan, China health plans have to be adapted continuously in response to the emergency. The first publications from the Chinese experience demonstrate an increase in the incidence of COVID-19 infections in patients over 60 years of age, a higher frequency of severe forms of the disease and therefore theoretical indications of orientation towards resuscitative care.

However, the first published data from Hubei province suggest a low benefit of resuscitation for patients between 70 and 80 years of age and null in patients over 80 years of age. These data question the individual benefit / risk balance of an orientation towards resuscitation for this category of patients, their quality of life and the concept of unreasonable obstinacy.

Among the covariates associated with resuscitation mortality described in the data published to date, cardiovascular comorbidities, certain biological covariates (LDH, creatinine, lymphocytes, neutrophils, TP, D-dimers, etc.), the time between the first symptoms and the entry into resuscitation have been identified.

The objective of this multicentric observational study is to determine the clinical and biological covariates predictive of mortality in the population of patients over 60 years of age admitted in intensive care unit, in particular by integrating functional and nutritional data from patients 1 month before COVID-19 infection.

Conditions

  • COVID-19 Disease, Severe Form

Interventions

OTHER

Group1

* Comorbidities (CIRS-G scale), * Functional status of the patient with * Clinical frailty scale (1 month before infection) * ADL score (1 month before infection) * Biological data * Blood group * TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin * Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count) * Resuscitation outcomes * LDH rate at the start of intensive care * PaO2 / FiO2 ratio at the start of intensive care * IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care * SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII * Delay between the appearance of the first signs of infection and admission to intensive care

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Claire Falandry, MD · Hospices Civils de Lyon

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2020-08-15
Completion
2020-08-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04422340 on ClinicalTrials.gov